Browsing Conference Papers by Author "29572983 - Venter, J.D."

Now showing items 1-4 of 4

    • Determination of the therapeutic efficacy of a novel Pheroid® formulation in a rodent tuberculosis model 

      Van der Merwe, Drieke; Venter, Kobus; Grobler, Anne; Cloete, Theunis; Lemmer, Yolandy (Elsevier, 2019)
      Resistance against the current TB treatment regimens is spreading. A combination of the current TB regime with a novel drug delivery system, might lead to reduced resistance, shorter treatment durations and increased ...

    • The effect of entrapment of a peptide in Pheroid® on pharmacokinetics and testosterone levels 

      Hayeshi, Rose; Erasmus, Linné; Scholtz, Liezl-Marie; Venter, Kobus; Bester, Cor; Fick, Antoinette; Leussa, Nyango-Nkeh Adrienne; Grobler, Anne (Elsevier, 2019)
      Goserelin is a peptide drug that suppresses levels of testosterone and oestradiol [1]. The current formulation is presented in a sustained-release depot with several approved indications such as treatment of endometriosis, ...

    • Establishment and characterization of allograft and xenograft cancer rodent models 

      Koatale, Palesa; Okem, Ambrose; Venter, Kobus; Fick, Antoinette; Bester, Cor; Hayeshi, Rose (Elsevier, 2019)
      To evaluate the efficacy of newly synthesized therapies prior to clinical trials, valid and true cancer models should be used [1]. For modelling cancer in vivo, transplantation of rodent (allograft) and human cancer ...

    • Evaluation of the oral delivery of a peptide with Pheroid® technology 

      Erasmus, Linné; Scholtz, Liezl-Marie; Venter, Kobus; Bester, Cor; Fick, Antoinette; Mabena, Jacob; Grobler, Anne; Hayeshi, Rose (Elsevier, 2019)
      Goserelin is a type of hormone therapy used in addition to standard adjuvant therapy. Currently, goserelin is only available as a slow releasing subcutaneous implant but this is an invasive and generally not well- tolerated ...